Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multicenter Single-arm Extension Study of AMG 416 in Secondary Hyperparathyroidism
2013-004136-30Phase 3Completed
- Sponsor
- KAI Pharmaceuticals
- Start
- Dec 2013
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of etelcalcetide in secondary hyperparathyroidism (SHPT) and chronic kidney disease (CKD), sponsored by KAI Pharmaceuticals. Primary endpoint: Subject incidence of adverse events reported throughout the study. Started Dec 2013; status: completed.
02
Drugs
etelcalcetide
03
Conditions
secondary hyperparathyroidism (SHPT)chronic kidney disease (CKD)
Beyond the preview
Go deeper on 2013-004136-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-004136-30.